首页/数据集/Demographics and baseline clinical characteristics of Phase 1 study participants at MIT.

Demographics and baseline clinical characteristics of Phase 1 study participants at MIT.

NIAID Data Ecosystem2026-03-14 收录

数据链接：

https://figshare.com/articles/dataset/Demographics_and_baseline_clinical_characteristics_of_Phase_1_study_participants_at_MIT_/21662245 数据链接链接失效反馈

官方服务：

资源简介：

Demographics and baseline clinical characteristics of Phase 1 study participants at MIT.

应用场景：

创建时间：

2022-12-01

I期临床试验

转移性结直肠癌治疗

TSB-9-W1, prepared by Taiwan Sunpan Biotechnology Co., Ltd. (TSB) is a botanical drug and applied patent in the United States (US patent No. 7,138,428 B2), Japan (Patent No. 5441947) and Taiwan (Paten

NIAID Data Ecosystem80

Dataset from A Phase I, Double-Blind, Two-Part, Sequential Study to Evaluate the Pharmacokinetics of Gepotidacin Tablets in Healthy Adult and Adolescent Participants

药代动力学

I期临床试验

This is double-blind, randomized, sequential, two part study. Part 1 is a 3 periods, fixed-sequence study and will be conducted to evaluate the pharmacokinetics, safety, and tolerability of the gepo

NIAID Data Ecosystem30

Age and sex distribution in different dosing groups during phase 1 clinical trial.

I期临床试验

人口统计学

Age and sex distribution in different dosing groups during phase 1 clinical trial.

NIAID Data Ecosystem20

Dataset from A Randomized, Placebo-controlled, Double-Blind (Sponsor Unblind), Repeat Dose, Ascending Cohort, Dose Escalation Phase I Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Epelsiban and Its Major Metabolite in Healthy Women Volunteers Following Administration of Repeat Dosing of Epelsiban

I期临床试验

药代动力学与安全性评估

The current study is designed to assess the safety, tolerability and pharmacokinetics (PK) of additional repeat doses of epelsiban in healthy females, and will be the first dosing experience of repeat

NIAID Data Ecosystem30

Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors

I期临床试验

药代动力学剂量探索

SNB-101 is a novel nano-particle formulation of SN-38, the active metabolite of irinotecan(CPT-11). Study SNB101P01 is a multicenter, open-label, dose escalation, phase 1 study of SNB 101 with its act

NIAID Data Ecosystem20

Demographics and baseline clinical characteristics of Phase 1 study participants at MIT.

资源简介：

相关数据集